The fight against breast cancer is not one-dimensional.
At Fujifilm, we are committed to doing our part, at every opportunity, to deliver
value through imaging innovation. ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) is built
smarter because it is built with insight into image quality, operational excellence, and a better
It's time to get smarter about 3D mammography
ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) is built with insight into image quality,
operational excellence, and a better patient experience. Here's why:
Mammograms don't work if women won't get them.
The intelligent design of ASPIRE
Cristalle's patented Comfort Paddle provides noticeably less pain and anxiety for the patient. With its
unique flexible, slotted 4-way tilting paddle design, it provides more even compression, that combined
with the Intelligent Automatic Exposure Control (iAEC) image processing, make it possible to provide
more optimized images at low dose for every breast type, including implants.
Departments are only as efficient as the technology they use.
technology simplifies and speeds workflow so technologists can spend more time focused on patient
Smart shortcuts and fewer clicks—set exposure and confirm acquired images on a single screen
Simultaneously adjust density and contrast for both left and right views
Minimize patient discomfort with automated compression and release
Immediately output individual images to PACS, viewer, or printer during exam
Improve system availability and extend system life with programmable automatic startup, sleep,
INSIGHT #3 Hexagons are engineered to perform better than square.The unique Hexagonal
Close Pattern (HCP) detector pixel design on ASPIRE Cristalle outperforms traditional pixel arrays to
help enable superior diagnostic accuracy for radiologists.
When compared to square pixels, HCP
20% increase in detector sensitivity
Improved information capture
Lower patient dose
INSIGHT #4 You may be ready for tomosynthesis, but your IT infrastructure might not
be.It's critical to think about the bigger picture when introducing DBT to your facility to
keep your facility running as efficiently as possible. Our Synapse® Enterprise Imaging portfolio,
including Synapse 5 PACS and Synapse VNA, enables secure, easy-to-manage storage and access to the
complete patient imaging record throughout the healthcare enterprise, regardless of the
technology-generating source, format type, or siloed storage system.
Digital Breast Tomosynthesis (DBT)
Radiologists using ASPIRE Cristalle with DBT will realize valuable, enhanced clinical efficacy compared
to using full field digital mammography (FFDM) alone.
DBT acquires a series of low-dose images at different angles. The acquired images are
reconstructed into a series of high-resolution slices displayed individually or dynamically in a
The reconstructed tomographic images make it easier to identify lesions which might otherwise be
difficult to visualize in traditional 2D mammogram images because of the presence of overlapping
Superior diagnostic accuracy and superior (lower) recall rates for non-cancer cases are possible
with ASPIRE Cristalle's DBT technology.
Hexagonal Close Pattern (HCP) Direct Conversion Technology
50-micron image display
Reduced acquisition time — only 15 seconds
Hexagonal pixels distribute the electrical field more efficiently than traditional square
pixels, to capture stronger signals with less noise
Resulting images have high DQE and MTF, producing brilliant image quality
Offers exceptionally sharp images, even at low dose
iAEC plus ISC: Optimized x-ray dose and contrast for each breast type
The unique Comfort Paddle allows pressure to be more evenly and gently distributed across the breast
compared to conventional, flexible paddles.
Slotted paddle edge allows plate to flex to the contour of the breast
Bends from center of breast to thinner edges
Distributes pressure more evenly
Tilting paddle allows for more gradual and more even compression
Available in two sizes to accommodate different breast sizes: 18x24cm and 24x30cm
Available standard on ASPIRE Cristalle, optional on ASPIRE HD Plus
ASPIRE Cristalle Advances the State of the Art in Digital Mammography
ASPIRE Cristalle, Fujifilm’s third-generation full-field digital mammography (FFDM) system, now delivers
optimum image quality at a very low patient dose. A new white paper, Technology Advances in Mammography:
Dose Reduction and Image Quality, highlights the recent advances in FFDM technology employed in the
ASPIRE Cristalle system.
Download the white paper to learn how:
ASPIRE Cristalle’s novel Hexagonal Close Pattern detector yields improved sensitivity compared
to conventional detectors while reducing patient dose by approximately 20%.
Adaptive and analytical image processing automatically adjusts to each patient's breast
A quality-control package consisting of the 1 Shot Phantom M Plus and corresponding QC software
facilitates a comprehensive mammography quality-control program.
Fujifilm works with the following partners to provide additional features for ASPIRE Cristalle,
ASPIRE HD Plus and ASPIRE HD.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image
analysis, workflow solutions and radiation therapies for the early identification and treatment of
common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for
mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for
breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD's Xoft System, offers
radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative
Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the
treatment of non-melanoma skin cancer and gynecological cancers.
Volpara Solutions builds innovative, quantitative breast imaging solutions tools built on the Volpara
algorithm which enables the generation of volumetric measurements of density, patient specific dose,
breast compression and other factors that provide actionable intelligence designed to help maintain
accuracy and consistent quality in breast screening.
To date, more than 2 million women have had
their volumetric breast density analyzed using VolparaDensity. Cleared by the FDA, HealthCanada, the TGA
and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital
mammography and tomosynthesis images and help evaluate who might benefit from additional screening.
Highly correlated to breast MR assessments, VolparaDensity is a reliable tool which automatically
generates an objective, automatic measurement of volumetric breast density and a FDA cleared BI-RADS
breast density category.
VolparaAnalytics assists in quality assurance by monitoring critical
elements of the breast imaging process and generating key metrics to help understand the performance of
technologists, readers, and mammography and tomosynthesis machines.
VolparaDose improves the
accuracy of mammography dose reporting by using a standard mean glandular dose (MGD) algorithm along
with patient-specific volumetric breast density to give a better estimate of the dose absorbed by the